Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

A method for producing a carbon dioxide-containing hydrogel article including (1) to (3). (1) Preparing an article including a hydrogel that contains a water-soluble polymer, a cross-linking agent for the water-soluble polymer, and water, wherein a loss tangent of the hydrogel at 1 Hz in dynamic viscoelasticity measurement is 0.46 or greater. (2) Adjusting a composition of an ambient atmosphere of the article including the hydrogel such that a carbon dioxide gas concentration in the ambient atmosphere becomes 10 vol% or greater, and sealing the article including the hydrogel inside a package. (3) Making cross-linking of the hydrogel proceed until the loss tangent, at 1 Hz in dynamic viscoelasticity measurement, of the hydrogel in the article including the hydrogel becomes less than 0.46, and thereby obtaining a carbon dioxide-containing hydrogel article sealed inside the package.

Disclosed are methods of increasing blood circulation at a target site of a subject comprising exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the target site of the subject to a vasodilator, wherein the vasodilator increases blood circulation at the target site of the subject. Disclosed are methods of maintaining or decreasing temperature at a target site of a subject comprising exposing a target site of the subject to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the target site of the subject to a vasodilator, wherein the vasodilator increases circulation at the target site of the subject, wherein increased circulation maintains or decreases temperature at the target site.

Systems and methods for artificial intelligence enable control of hemodyamics in an individual are provided. A number of embodiments use a phenotypic response surface (PRS) that describes a physiological response to a vasopressor and/or a vasodilator to guide administration of the vasopressor and/or vasodilator. Various embodiments continually update the PRS based on changes in physiological response to the vasopressor and/or vasodilator.

Systems and methods for artificial intelligence enable control of hemodyamics in an individual are provided. A number of embodiments use a phenotypic response surface (PRS) that describes a physiological response to a vasopressor and/or a vasodilator to guide administration of the vasopressor and/or vasodilator. Various embodiments continually update the PRS based on changes in physiological response to the vasopressor and/or vasodilator.

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.

Provided are peptides that based on the amino acid sequences LDPAKDCGDQKYAY (SEQ ID NO: 1) and LDPSKDCGDPKYAY (SEQ ID NO: 2), optionally wherein the peptide includes an N-terminal stearate modification. Also provided are method for using the disclosed peptides for inhibiting neointima formation in mammals, methods for inhibiting division and/or proliferation of vascular smooth muscle cells, and uses of the disclosed peptides for treating cardiovascular diseases and/or disorder associated with undesirable vascular SMC proliferation, which in some embodiments can re-late to inhibiting neointima formation in a mammal.

A composition may be used in vascular relaxation, wherein the composition may include one or more anthocyanins.